Padmini Salgame
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Padmini Salgame has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
Jerrold J. Ellner
Department of Medicine and Public Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ, United States
11 shared publications- Charles Robert Horsburgh
Department of Epidemiology, Boston University School of Public Health , Boston, Massachusetts
10 shared publications - Jerrold J. Ellner
Department of Medicine, Center for Emerging Pathogens, Rutgers New Jersey Medical School , Newark, New Jersey
10 shared publications - Sonali Sarkar
Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
10 shared publications - Subitha Lakshminarayanan
Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
7 shared publications - Natasha S. Hochberg
Boston University School of Medicine
6 shared publications
Latest Publications
- 8 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Attenuated Mycobacterium tuberculosis -Specific Th1 Cytokine Responses in Household Contacts With Undernutrition and Their Partial Reconstitution During 6 Months of Nutritional Support
Background: Undernutrition is the leading population-attributable risk factor for tuberculosis (TB), yet whether associated immune impairments are reversible with nutritional rehabilitation remains unclear. Methods: In Tuberculosis: Learning the Impact of Nutrition (Puducherry, India), 105 QuantiFERON-positive household contacts were stratified by body mass index (BMI) (<18.5 vs ≥18.5 kg/m2). Participants with low BMI (n = 53) received 6 months of food rations plus a daily multiple micronutrient supplement (MMS) without iron. Fourteen cytokines were measured by Luminex in supernatants from the unstimulated (Nil) and Mycobacterium tuberculosis (Mtb)-antigen-stimulated (TB2) IGRA assays at baseline and 6 months; 11 with acceptable detection rates constituted the primary analytic set. Linear regression tested associations of weight and hemoglobin change with composite immune pathway scores. Results: At baseline, participants with low BMI had attenuated Mtb-specific Th1 cytokine responses (interaction geometric mean ratio [GMR] 0.70 for IFN-γ, 0.55 for IL-2; both P = .005), despite comparable or elevated innate and regulatory cytokines. After 6 months, Th1 responses increased (interferon gamma change GMR 1.41, 95% CI 1.10–1.80, P = .005, q = 0.06; interleukin-2 1.63, 1.01–2.63, P = .046, q = 0.25, suggestive). This increase reflected falling unstimulated background, not higher stimulated output. Weight gain was unrelated to composite scores but associated with elevated concentrations of 7 of 14 cytokines (all P < .05). Hemoglobin gain was inversely associated with Th17 and proinflammatory scores but not Th1. Conclusions: Six months of combined food rations and daily MMS were followed by improved antigen-specific Th1 cytokine responses, suggesting that this impairment may be partially reversible on a clinically feasible timescale. As a single-arm study without a concurrent comparator with undernutrition measured at follow-up, observed changes cannot be causally attributed to the intervention. Clinical Trials Registration: NCT03598842.
- 8 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Attenuated Mycobacterium tuberculosis -Specific Th1 Cytokine Responses in Household Contacts With Undernutrition and Their Partial Reconstitution During 6 Months of Nutritional Support
Background: Undernutrition is the leading population-attributable risk factor for tuberculosis (TB), yet whether associated immune impairments are reversible with nutritional rehabilitation remains unclear. Methods: In Tuberculosis: Learning the Impact of Nutrition (Puducherry, India), 105 QuantiFERON-positive household contacts were stratified by body mass index (BMI) (<18.5 vs ≥18.5 kg/m2). Participants with low BMI (n = 53) received 6 months of food rations plus a daily multiple micronutrient supplement (MMS) without iron. Fourteen cytokines were measured by Luminex in supernatants from the unstimulated (Nil) and Mycobacterium tuberculosis (Mtb)-antigen-stimulated (TB2) IGRA assays at baseline and 6 months; 11 with acceptable detection rates constituted the primary analytic set. Linear regression tested associations of weight and hemoglobin change with composite immune pathway scores. Results: At baseline, participants with low BMI had attenuated Mtb-specific Th1 cytokine responses (interaction geometric mean ratio [GMR] 0.70 for IFN-γ, 0.55 for IL-2; both P = .005), despite comparable or elevated innate and regulatory cytokines. After 6 months, Th1 responses increased (interferon gamma change GMR 1.41, 95% CI 1.10–1.80, P = .005, q = 0.06; interleukin-2 1.63, 1.01–2.63, P = .046, q = 0.25, suggestive). This increase reflected falling unstimulated background, not higher stimulated output. Weight gain was unrelated to composite scores but associated with elevated concentrations of 7 of 14 cytokines (all P < .05). Hemoglobin gain was inversely associated with Th17 and proinflammatory scores but not Th1. Conclusions: Six months of combined food rations and daily MMS were followed by improved antigen-specific Th1 cytokine responses, suggesting that this impairment may be partially reversible on a clinically feasible timescale. As a single-arm study without a concurrent comparator with undernutrition measured at follow-up, observed changes cannot be causally attributed to the intervention. Clinical Trials Registration: NCT03598842.
- Open Access
- 3 May 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 169, 108763
Development of a four-gene host signature for paucibacillary TB among symptomatic individuals with sputum Xpert MTB/RIF Ultra very low and trace results
- 3 May 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 169, 108763
Open AccessDevelopment of a four-gene host signature for paucibacillary TB among symptomatic individuals with sputum Xpert MTB/RIF Ultra very low and trace results
- Open Access
- 10 April 2026
- Published by Frontiers Media SA in Frontiers in Tuberculosis
- Vol. 4
Immunometabolic reprogramming of Mycobacterium tuberculosis-responsive memory CD4+ T cell subsets is linked to long-term protective immunity
Introduction: Memory CD4 + T cells are central to long-term immunity in tuberculosis (TB), yet their functional roles that define their protective capacity remain unclear. Understanding the immune mechanisms that prevent clinical progression from latent TB infection (LTBI) to active TB disease is critical for the development of next-generation vaccines and biomarkers. Methods: We characterized the transcriptomic, metabolic, and functional programs of Mycobacterium tuberculosis (Mtb) antigen-stimulated peripheral CD4 + T stem cell (T-SCM), central (T-CM), transitional (T-TM), and effector (T-EM) memory subsets from individuals with remote LTBI. We utilized a multi-platform validation strategy that integrated RNA-sequencing data with protein-level metabolic profiling using “Met-Flow” cytometry and functional growth restriction assays to link memory CD4 + T cell differentiation states to immunometabolism and antimycobacterial function. Finally, we evaluated the immunometabolic profiles of memory CD4 + T cell subsets in an independent, longitudinal cohort of Mtb-exposed progressors and non-progressors from Brazil (GSE112104). Results: We identified a differentiation gradient associated with distinct immunometabolic states. T-SCM and T-CM subsets exhibited elevated mitochondrial activity and oxidative metabolism (fatty acid oxidation), supporting their proliferative capacity. In contrast, T-TM and T-EM subsets underwent glycolytic reprogramming and engaged the pentose phosphate pathway, which fueled enhanced cytokine production and Mtb growth restriction. Importantly, we observed that non-progressors exhibit fatty acid oxidation-driven, stem/central memory-like signatures, while progressors and active TB cases display elevated exhaustion markers, glycolytic reprogramming and pro-inflammatory profiles aligned with disease progression. Conclusion: Collectively, findings from our proof-of-concept study suggest metabolic state as a key axis connecting Mtb antigen-induced memory T cell differentiation, restimulation-induced transcriptional programming, and durability of immune control. The findings provide the basis for future longitudinal studies to examine the dynamic metabolic and functional modulation in Mtb antigen-specific memory T cell subsets from contained infection to disease progression.
- 10 April 2026
- Published by Frontiers Media SA in Frontiers in Tuberculosis
- Vol. 4
Open AccessImmunometabolic reprogramming of Mycobacterium tuberculosis-responsive memory CD4+ T cell subsets is linked to long-term protective immunity
Introduction: Memory CD4 + T cells are central to long-term immunity in tuberculosis (TB), yet their functional roles that define their protective capacity remain unclear. Understanding the immune mechanisms that prevent clinical progression from latent TB infection (LTBI) to active TB disease is critical for the development of next-generation vaccines and biomarkers. Methods: We characterized the transcriptomic, metabolic, and functional programs of Mycobacterium tuberculosis (Mtb) antigen-stimulated peripheral CD4 + T stem cell (T-SCM), central (T-CM), transitional (T-TM), and effector (T-EM) memory subsets from individuals with remote LTBI. We utilized a multi-platform validation strategy that integrated RNA-sequencing data with protein-level metabolic profiling using “Met-Flow” cytometry and functional growth restriction assays to link memory CD4 + T cell differentiation states to immunometabolism and antimycobacterial function. Finally, we evaluated the immunometabolic profiles of memory CD4 + T cell subsets in an independent, longitudinal cohort of Mtb-exposed progressors and non-progressors from Brazil (GSE112104). Results: We identified a differentiation gradient associated with distinct immunometabolic states. T-SCM and T-CM subsets exhibited elevated mitochondrial activity and oxidative metabolism (fatty acid oxidation), supporting their proliferative capacity. In contrast, T-TM and T-EM subsets underwent glycolytic reprogramming and engaged the pentose phosphate pathway, which fueled enhanced cytokine production and Mtb growth restriction. Importantly, we observed that non-progressors exhibit fatty acid oxidation-driven, stem/central memory-like signatures, while progressors and active TB cases display elevated exhaustion markers, glycolytic reprogramming and pro-inflammatory profiles aligned with disease progression. Conclusion: Collectively, findings from our proof-of-concept study suggest metabolic state as a key axis connecting Mtb antigen-induced memory T cell differentiation, restimulation-induced transcriptional programming, and durability of immune control. The findings provide the basis for future longitudinal studies to examine the dynamic metabolic and functional modulation in Mtb antigen-specific memory T cell subsets from contained infection to disease progression.
- Open Access
- 10 March 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (3) , e0052324
Post-TB lung disease: pathogenesis, host-directed therapies, and the C3HeB/FeJ model for pre-clinical advances
More than half of the people with microbiologically cured tuberculosis (TB) present with post-TB lung disease (PTLD). PTLD compromises long-term respiratory health and adds to the global burden of chronic lung diseases. Despite its prevalence, the mechanisms driving tissue damage in TB are not well understood. In this review, we discuss the global burden of PTLD, evaluate host-directed therapies as promising interventions, and highlight the C3HeB/FeJ mouse model as a powerful tool for advancing pre-clinical PTLD research.
- 10 March 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (3) , e0052324
Open AccessPost-TB lung disease: pathogenesis, host-directed therapies, and the C3HeB/FeJ model for pre-clinical advances
More than half of the people with microbiologically cured tuberculosis (TB) present with post-TB lung disease (PTLD). PTLD compromises long-term respiratory health and adds to the global burden of chronic lung diseases. Despite its prevalence, the mechanisms driving tissue damage in TB are not well understood. In this review, we discuss the global burden of PTLD, evaluate host-directed therapies as promising interventions, and highlight the C3HeB/FeJ mouse model as a powerful tool for advancing pre-clinical PTLD research.
- Open Access
Combining blood transcriptomic signatures improves the prediction of progression to tuberculosis among household contacts in Brazil
Tuberculosis remains a major health threat, infecting nearly a third of the world’s population. Of those infected, 5-10% progress from latent infection to active tuberculosis (TB) disease and biomarkers to identify which individuals will progress are needed to allow targeted prophylactic treatment. Several risk biomarkers have been developed to predict progression but have not been tested head-to-head on the same platform. Here, we used the NanoString platform and compared the performance of 15 published gene signatures in predicting progression at baseline in a household contact cohort. Expression of gene signatures was profiled in RNA extracted from whole blood and scored using GSVA and PLAGE. We found that specificity is enhanced by combining signatures and report that the performance of a combined signature that includes a newly derived parsimonious signature through machine learning and a published signature met WHO TPP levels for a triage test. The combined signature had a 90.9% sensitivity and 88% specificity with a PPV of 0.24 and NPV of 1. This combined signature has potential clinical utility in identifying high-risk individuals for targeted prophylaxis to prevent TB morbidity and mortality.
Open AccessCombining blood transcriptomic signatures improves the prediction of progression to tuberculosis among household contacts in Brazil
Tuberculosis remains a major health threat, infecting nearly a third of the world’s population. Of those infected, 5-10% progress from latent infection to active tuberculosis (TB) disease and biomarkers to identify which individuals will progress are needed to allow targeted prophylactic treatment. Several risk biomarkers have been developed to predict progression but have not been tested head-to-head on the same platform. Here, we used the NanoString platform and compared the performance of 15 published gene signatures in predicting progression at baseline in a household contact cohort. Expression of gene signatures was profiled in RNA extracted from whole blood and scored using GSVA and PLAGE. We found that specificity is enhanced by combining signatures and report that the performance of a combined signature that includes a newly derived parsimonious signature through machine learning and a published signature met WHO TPP levels for a triage test. The combined signature had a 90.9% sensitivity and 88% specificity with a PPV of 0.24 and NPV of 1. This combined signature has potential clinical utility in identifying high-risk individuals for targeted prophylaxis to prevent TB morbidity and mortality.
- 10 September 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (3) , 594-597
Rifampin Exposure in Pregnant and Nonpregnant Women With Tuberculosis in India
This prospective cohort study evaluated rifampin pharmacokinetics in pregnant and nonpregnant women with tuberculosis in India. Pregnant women had significantly lower drug exposure, with <20% of the participants achieving target concentrations at any trimester. Findings highlight potential underdosing in pregnancy and underscore the need for dedicated pharmacokinetics studies in pregnancy, and revised rifampin dosing guidelines.
- 10 September 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (3) , 594-597
Rifampin Exposure in Pregnant and Nonpregnant Women With Tuberculosis in India
This prospective cohort study evaluated rifampin pharmacokinetics in pregnant and nonpregnant women with tuberculosis in India. Pregnant women had significantly lower drug exposure, with <20% of the participants achieving target concentrations at any trimester. Findings highlight potential underdosing in pregnancy and underscore the need for dedicated pharmacokinetics studies in pregnancy, and revised rifampin dosing guidelines.
- Open Access
- 24 April 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 18 (7) , 102791
Prominence of Mycobacterium tuberculosis biomarkers among sputum culture-negative clinic attendees, independent of Ultra status
- 24 April 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 18 (7) , 102791
Open AccessProminence of Mycobacterium tuberculosis biomarkers among sputum culture-negative clinic attendees, independent of Ultra status
- Open Access
- 23 April 2024
- Published by Frontiers Media SA in Frontiers in Tuberculosis
- Vol. 2, 1378068
Diverse interactions of Mycobacterium tuberculosis infection and of BCG vaccination with SARS-CoV-2
The COVID pandemic and tuberculosis (TB) endemicity is double trouble to much of the world. SARS-CoV-2 and Mycobacterium tuberculosis (Mtb), causative agents of COVID and TB, respectively, are both infectious respiratory pathogens involving close communities and individuals. Both pathogens can cause lung disease, involving unbalanced inflammatory cell immune responses that can lead to a syndemic impact. Moreover, dual infection is common in certain settings. In low- and middle- income countries, most individuals with SARS-CoV-2 infection or COVID-19, in fact, will have been exposed to or infected with Mtb and some will develop active TB. Here we review the literature examining the diverse interactions of M. tuberculosis infection and of BCG vaccination with SARS-CoV-2. We discuss areas in which contradictory results have been published and conclude that there are still several unresolved issues that warrant further study on the co-pathogenesis of SARS-CoV-2 and Mtb and BCG- mediated heterologous protection against COVID-19.
- 23 April 2024
- Published by Frontiers Media SA in Frontiers in Tuberculosis
- Vol. 2, 1378068
Open AccessDiverse interactions of Mycobacterium tuberculosis infection and of BCG vaccination with SARS-CoV-2
The COVID pandemic and tuberculosis (TB) endemicity is double trouble to much of the world. SARS-CoV-2 and Mycobacterium tuberculosis (Mtb), causative agents of COVID and TB, respectively, are both infectious respiratory pathogens involving close communities and individuals. Both pathogens can cause lung disease, involving unbalanced inflammatory cell immune responses that can lead to a syndemic impact. Moreover, dual infection is common in certain settings. In low- and middle- income countries, most individuals with SARS-CoV-2 infection or COVID-19, in fact, will have been exposed to or infected with Mtb and some will develop active TB. Here we review the literature examining the diverse interactions of M. tuberculosis infection and of BCG vaccination with SARS-CoV-2. We discuss areas in which contradictory results have been published and conclude that there are still several unresolved issues that warrant further study on the co-pathogenesis of SARS-CoV-2 and Mtb and BCG- mediated heterologous protection against COVID-19.
- Open Access
High resolution imaging and five-year tuberculosis contact outcomes
Background: The evolution of tuberculosis (TB) disease during the clinical latency period remains incompletely understood. Methods: 250 HIV-uninfected, adult household contacts of rifampicin-resistant TB with a negative symptom screen underwent baseline 18 F-Fluorodeoxyglucose positron emission and computed tomography (PET/CT), repeated in 112 after 5-15 months. Following South African and WHO guidelines, participants did not receive preventive therapy. All participants had intensive baseline screening with spontaneous, followed by induced, sputum sampling and were then observed for an average of 4.7 years for culture-positive disease. Baseline PET/CT abnormalities were evaluated in relation to culture-positive disease. Results: At baseline, 59 (23.6%) participants had lung PET/CT findings consistent with TB of which 29 (11.6%) were defined as Subclinical TB, and 30 (12%) Subclinical TB-inactive. A further 83 (33.2%) had other lung parenchymal abnormalities and 108 (43.2%) had normal lungs. Over 1107-person years of follow-up 14 cases of culture-positive TB were diagnosed. Six cases were detected by intensive baseline screening, all would have been missed by the South African symptom-based screening strategy and only one detected by a WHO-recommended chest X-Ray screening strategy. Those with baseline Subclinical TB lesions on PET/CT were significantly more likely to be diagnosed with culture-positive TB over the study period, compared to those with normal lung parenchyma (10/29 [34.5%] vs 2/108 [1.9%], Hazard Ratio 22.37 [4.89-102.47, p<0.001]). Conclusions: These findings challenge the latent/active TB paradigm demonstrating that subclinical disease exists up to 4 years prior to microbiological detection and/or symptom onset. There are important implications for screening and management of TB.
Open AccessHigh resolution imaging and five-year tuberculosis contact outcomes
Background: The evolution of tuberculosis (TB) disease during the clinical latency period remains incompletely understood. Methods: 250 HIV-uninfected, adult household contacts of rifampicin-resistant TB with a negative symptom screen underwent baseline 18 F-Fluorodeoxyglucose positron emission and computed tomography (PET/CT), repeated in 112 after 5-15 months. Following South African and WHO guidelines, participants did not receive preventive therapy. All participants had intensive baseline screening with spontaneous, followed by induced, sputum sampling and were then observed for an average of 4.7 years for culture-positive disease. Baseline PET/CT abnormalities were evaluated in relation to culture-positive disease. Results: At baseline, 59 (23.6%) participants had lung PET/CT findings consistent with TB of which 29 (11.6%) were defined as Subclinical TB, and 30 (12%) Subclinical TB-inactive. A further 83 (33.2%) had other lung parenchymal abnormalities and 108 (43.2%) had normal lungs. Over 1107-person years of follow-up 14 cases of culture-positive TB were diagnosed. Six cases were detected by intensive baseline screening, all would have been missed by the South African symptom-based screening strategy and only one detected by a WHO-recommended chest X-Ray screening strategy. Those with baseline Subclinical TB lesions on PET/CT were significantly more likely to be diagnosed with culture-positive TB over the study period, compared to those with normal lung parenchyma (10/29 [34.5%] vs 2/108 [1.9%], Hazard Ratio 22.37 [4.89-102.47, p<0.001]). Conclusions: These findings challenge the latent/active TB paradigm demonstrating that subclinical disease exists up to 4 years prior to microbiological detection and/or symptom onset. There are important implications for screening and management of TB.
- Open Access
- 21 June 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1146571
Mechanisms of lung damage in tuberculosis: implications for chronic obstructive pulmonary disease
Pulmonary tuberculosis is increasingly recognized as a risk factor for COPD. Severe lung function impairment has been reported in post-TB patients. Despite increasing evidence to support the association between TB and COPD, only a few studies describe the immunological basis of COPD among TB patients following successful treatment completion. In this review, we draw on well-elaborated Mycobacterium tuberculosis-induced immune mechanisms in the lungs to highlight shared mechanisms for COPD pathogenesis in the setting of tuberculosis disease. We further examine how such mechanisms could be exploited to guide COPD therapeutics.
- 21 June 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1146571
Open AccessMechanisms of lung damage in tuberculosis: implications for chronic obstructive pulmonary disease
Pulmonary tuberculosis is increasingly recognized as a risk factor for COPD. Severe lung function impairment has been reported in post-TB patients. Despite increasing evidence to support the association between TB and COPD, only a few studies describe the immunological basis of COPD among TB patients following successful treatment completion. In this review, we draw on well-elaborated Mycobacterium tuberculosis-induced immune mechanisms in the lungs to highlight shared mechanisms for COPD pathogenesis in the setting of tuberculosis disease. We further examine how such mechanisms could be exploited to guide COPD therapeutics.